anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The randomized controlled study will be conducted in order to evaluate the effects of individual needs of physical exercise, nutrition, and symptom management in patients with heart failure who are frail and older. Patients discharged from a geriatric hospital will be recruited and included after informed consent. Two weeks after hospital discharge patients are randomized to intervention or control group. The intervention period is 3 months. With support from a physioterapeut, dietician and a registered nurse, the intervention will be performed in the participants´ home. Once a week participants will come to the hospital for physical exercise led by a physiotherapist. Once a week or every other week participants will meet a dietician and a nurse. Data will be collected at baseline, and 3 and 6 months after baseline. Data consist of e.g. study flow description, number of eligible patients, number of drop-outs, patients sociodemographic- and clinical data, physical function and performance, nutritional status, symptom burden, self-care, appetite, thirst, health-related quality of life. At 12 months after baseline, data will be collected on hospital admissions, reasons for hospital admissions, length of stay and mortality.
Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Venofer. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. If hypersensitivity reactions or signs of intolerance occur during administration, stop Venofer immediately. Monitor patients for signs and symptoms of hypersensitivity during and after Venofer administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Venofer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Most reactions associated with intravenous iron preparations occur within 30 minutes of the completion of the infusion [see Adverse Reactions (6.1 and 6.2)].
Vials should be used only for subcutaneous administration and not intravenous infusion. Sterility and accurate dosing cannot be assured if the vials are not used in accordance with DOSAGE AND ADMINISTRATION.

Discard unused portion after single patient use.

The usual subcutaneous dose of terbutaline sulfate injection is 0.25 mg injected into the lateral deltoid area. If significant clinical improvement does not occur within 15 to 30 minutes, a second dose of 0.25 mg may be administered. If the patient then fails to respond within another 15 to 30 minutes, other therapeutic measures should be considered. The total dose within 4 hours should not exceed 0.5 mg.

Note: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
A device exchange transports messages between autonomous devices in a medical environment. The autonomous devices perform various tasks in the medical environment, such as surgical device control, drug infusion, video recordation, and user interfaces, for example. Each autonomous device has a device specification, published and stored by the device exchange and available to other autonomous devices. The device specification indicates, for each autonomous device, an identifier, a set of outputs and a set of inputs, or commands. Devices interoperate by messages including the device identifier and an output or command without translation or transformation mechanisms such as scripts, protocol translations, drivers or interface modules because each message is based on the published device specification available to all the devices connected to the exchange. Interconnected medical devices therefore interoperate without the need for reconfiguration because each device has internal logic for understanding the messages it sends and receives via the exchange.
Data collection tools from mothers in the control group after admission to the intensive care unit \[Descriptive Characteristics Form, Parental Stress Scale: (Pediatric Intensive Care Unit), Empowerment of Parents in The Intensive Care (EMPATHIC-30) (Empowerment of Parents in Intensive Care Scale), Decision Data will be collected using the Conflict in Making and Decision Making Confident Scale (KVÇS and KEOÖ). The routine operation of the intensive care unit will continue and data will be collected again after 5 days of hospitalization.
The experimental arm will be treated with 4 cycles of POR regimen （Pomalidomide 4mg d1-d14, Orelabrutinib 150mg d1-d21, Rituximab 375mg/m2 d1, 21 days per cycle). The response will be evaluated every 2 cycles. The patients with PD will drop out of the study.Patients with CR/PR/SD after 4 cycles of POR treatment will be treated with 2 cycles of RO-MTX regimen（methotrexate 3.5g/m2 civ d1, Orelabrutinib 150mg d1-d21, Rituximab 375mg/m2 d1, 21 days per cycle).
The disclosure provides substituted fused bicyclic compounds as PARP inhibitors and the the use thereof. This disclosure provides compounds represented by Formula I as below, wherein A 1 . A 2 , A 3 , R 1 , L, Cy and n are defined herein. The compounds of Formula I of the present disclosure are PARP inhibitors and thus are useful in the treatment of diseases, disorders and conditions, such as cancer. responsive to the inhibition of PARP activity. The present disclosure also relates to a pharmaceutical composition comprising the compound of Formula I and the use of the compound of Formula I in the preparation of a medicament for the treatment or prevention of diseases or conditions responsive to the inhibition of PARP activity.
Novel metabolites and enzymes involved in skatole metabolism are disclosed. The novel metabolites are 3-OH-3-methylindolenine (HMI); 3-methyloxindole (3MOI); indole-3-carbinol (I-3C); and 2-aminoacetophenone (2-AM). Measuring levels of these metabolites in a pig may be useful in identifying the pig's ability to metabolize skatole and its susceptibility to boar taint. The novel enzymes involved in skatole metabolism are aldehyde oxidase and CYP2A6. Enhancing the activity of these enzymes may be useful in enhancing skatole metabolism and reducing boar taint. The identification of the enzyme also allows the development of screening assays for substances that interact with these enzymes and skatole metabolism or for genetic screening to identify pigs on the basis of their skatole metabolism. Pigs having high levels of these enzymes may be selected and bred to produce pigs that have a lower incidence of boar taint.
INFUMORPH contains morphine, a Schedule II controlled substance. As an opioid, INFUMORPH exposes users to the risks of addiction, abuse, and misuse [see Drug Abuse and Dependence (9)].

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed INFUMORPH. Addiction can occur at recommended dosages and if the drug is misused or abused.

Assess each patient’s risk for opioid addiction, abuse, or misuse prior to prescribing INFUMORPH, and monitor all patients receiving INFUMORPH for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient.  
Patients at increased risk may be prescribed opioids such as INFUMORPH but use in such patients necessitates intensive counseling about the risks and proper use of INFUMORPH along with intensive monitoring for signs of addiction, abuse, and misuse.

Opioids are sought for nonmedical use and are subject to diversion from legitimate prescribed use. Consider these risks when prescribing or dispensing INFUMORPH. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity. Contact local state professional licensing board or state-controlled substances authority for information on how to prevent and detect abuse or diversion of this product.

Each ampul of INFUMORPH contains a large amount of a potent narcotic which has been associated with abuse and dependence among health care providers. Due to the limited indications for this product, the risk of overdosage and the risk of its diversion and abuse, it is recommended that special measures must be taken to control this product within the hospital or clinic. INFUMORPH should be subject to rigid accounting, rigorous control of wastage, and restricted access.
The invention relates to a bifunctional peptide. The bifunctional peptide comprises a tumor-cell apoptosis peptide and a cell-penetrating peptide. The invention also relates to a composite formed by the bifunctional peptide and a nucleic acid molecule and applications of the composite in treating tumor. The invention also relates to a pharmaceutical composite which comprises the bifunctional peptide, a tumor treating gene and a chemotherapeutic medicine and is used for treating tumor and tumor multidrug resistance, and applications of the pharmaceutical composite. The bifunctional peptide can induce tumor-cell apoptosis and promote the peptide and the composites thereof to penetrate through cytomembranes. The pharmaceutical composite combines the bifunctional peptide, the tumor treating gene and the chemotherapeutic medicine, and is capable of reducing the dosage of the chemotherapeutic medicine so as to significantly reduce toxic and side effects on organisms, inhibiting growth of tumor cells and effectively resisting the tumor multidrug resistance.
Participants will complete two MRI scans approximately one hour apart - one under baseline conditions and the second during an insulin infusion. Each scan will include data collected during rest, and a taste task. The taste task involves receiving milkshake or a tasteless solution. After the first scan, an isoglycemic-hyperinsulinemic clamp will be implemented. An IV will be placed in the antecubital vein of of arm for infusion of insulin and dextrose. HumuLIN®-R regular insulin will be infused at 40 mU/m2/min. A second IV will be inserted in the back of the hand on the opposite arm to allow for frequent sampling of blood glucose levels. Dextrose infusion will be used to keep the blood sugar level within 5mg/dl of the baseline value. The study team will monitor blood glucose levels and adjust dextrose infusions as necessary. Thirty minutes after starting the insulin infusion, participants will be moved back into the bore of the MRI scanner for the repeat scans.
PURPOSE:To obtain a stable amphoteric polyelectrolyte inexpensively by (co) polymerizing (meth)acrylic acid in water, reacting the obtained polymer with a specified amount of an alkyleneimine and acidifying the product with a monobasic acid. CONSTITUTION:An anionic monomer comprising (meth)acrylic acid is polymerized or copolymerized with a nonionic monomer (e.g. acrylamide) in water. The obtained vinylic carboxylic acid polymer is aminoalkylated by reaction with an alkyleneimine (e.g. ethyleneimine) in a molar ratio to the anionic monomer >=1.2, and the product is acidified with a monobasic acid. In this way, an amphoteric polyelectrolyte having aminoalkyl and carboxyl groups and represented by the formula (wherein (n) is 1-5; (a)+(b)+(c)=1; R1, R2, R3, R4 and R5 are each H, an alkyl or the like; HY is a monobasic acid; and Z is an amido, a hydroxyalkyl or a nitrile) can be obtained.
The present invention relates to Drosophila models of the neurodegenerative disorder spinocerebellar ataxia 1 (SCA-1). In particular, the invention relates to transgenic Drosophila which express normal human ataxin-1 or mutant human ataxin-1 with expanded polyglutamine repeats for SCA-1 therapeutics. The invention further relates to the diagnosis of predispositions to developing SCA-1. The invention further relates to methods of using the transgenic Drosophila to screen for therapeutics of SCA-1 and other neurodegenerative disorders. The invention further relates to the identification of modifier genes of the SCA-1 phenotypes produced by overexpression of ataxin-1, for therapeutic and diagnostic uses and for screening for therapeutics of SCA-1 and other neurodegenerative disorders. The invention further relates to the diagnosis of a predisposition to SCA-1 comprising detecting the overexpression of normal ataxin-1.
These patients receive a series of 10 Real Transcranial Magnetic Stimulation, Repetitive (rTMS), treatments, only. There is pre-testing, and post-testing at 2 months after the last Real rTMS treatment.
Advanced Amino acid-based ORS: VS002A Traditional oral rehydration solutions (ORS) contain sugars which stimulate intestinal sodium and water absorption through a variety of mechanisms. However, it has been under-appreciated that traditional ORS possess no anti-diarrheal functions and may exacerbate infectious diarrheal secretions.
PURPOSE:To obtain an analgesic composition for dental use, effectively adhering to tooth and continuously exhibiting excellent analgesic action for a long period, by compounding ethyl aminobenzoate and eugenol to a hydrophobic base compounded with traganth rubber powder. CONSTITUTION:Powder of traganth rubber passing a 200 mesh sieve is compounded to a hydrophobic base such as white vaseline, plastibase, etc., and the mixture is further compounded with ethyl aminobenzoate and eugenol as active components. If necessary, the base may be compounded with a local anesthetic, an anti-inflammation agent, a perfumery, etc. The above components are uniformly mixed and processed to a form of medicine to obtain the objective composition. The amounts of ethyl aminobenzoate, eugenol and traganth rubber powder are 5-20wt%, 3-8wt% and 10-40wt% based on the whole composition, respectively. The hydrophobic base is preferably a mixture of white vaseline and plastibase at a weight ratio of 1/4-2/1.
Participants will be instructed to brush the whole mouth (all teeth) for 1-timed minute, twice daily (morning and evening) with Crest Cavity Protection Fresh Lime. After brushing, participants will be instructed to rinse once with 10 mL of water using the measuring cup provided.
BACKGROUND: Sepsis-induced acute lung injury (ALI) is associated with considerable morbidity and mortality in critically ill patients. S100A9, a key endothelial injury factor, is markedly upregulated in sepsis-induced ALI; however, its specific mechanism of action has not been fully elucidated.
METHODS: The Gene Expression Omnibus database transcriptome data for sepsis-induced ALI were used to screen for key differentially expressed genes (DEGs). Using bioinformatics analysis methods such as Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and protein-protein interaction network analyses, the pathogenesis of sepsis-induced ALI was revealed. Intratracheal infusion of lipopolysaccharide (LPS, 10 mg/kg) induced ALI in wild-type (WT) and S100A9 knockout mice. Multiomics analyses (transcriptomics and proteomics) were performed to investigate the potential mechanisms by which S100A9 exacerbates acute lung damage. Hematoxylin-eosin, Giemsa, and TUNEL staining were used to evaluate lung injury and cell apoptosis. LPS (10 μg/mL)-induced murine lung epithelial MLE-12 cells were utilized to mimic ALI and were modulated by S100A9 lentiviral transfection. The impact of S100A9 on cell apoptosis and inflammatory responses were identified using flow cytometry and PCR. The expression of interleukin (IL)-17-nuclear factor kappa B (NFκB)-caspase-3 signaling components was identified using western blotting.
RESULTS: Six common DEGs (S100A9, S100A8, IFITM6, SAA3, CD177, and MMP9) were identified in the six datasets related to ALI in sepsis. Compared to WT sepsis mice, S100A9 knockout significantly alleviated LPS-induced ALI in mice, with reduced lung structural damage and inflammatory exudation, decreased exfoliated cell and protein content in the lung lavage fluid, and reduced apoptosis and necrosis of pulmonary epithelial cells. Transcriptomic analysis revealed that knocking out S100A9 significantly affected 123 DEGs, which were enriched in immune responses, defense responses against bacteria or lipopolysaccharides, cytokine-cytokine receptor interactions, and the IL-17 signaling pathway. Proteomic analysis revealed that S100A9 knockout alleviated muscle contraction dysfunction and structural remodeling in sepsis-induced ALI. Multiomics analysis revealed that S100A9 may be closely related to interferon-induced proteins with tetratricopeptide repeats and oligoadenylate synthase-like proteins. LPS decreased MLE12 cell activity, accompanied by high expression of S100A9. The expression of IL-17RA, pNFκB, and cleaved-caspase-3 were increased by S100A9 overexpression and reduced by S100A9 knockdown in LPS-stimulated MLE12 cells. S100A9 knockdown decreases transcription of apoptosis-related markers Bax, Bcl and caspase-3, alleviating LPS-induced apoptosis.
CONCLUSIONS: S100A9 as a key biomarker of sepsis-induced acute lung injury, and exacerbates lung damage and epithelial cell apoptosis induced by LPS via the IL-17-NFκB-caspase-3 signaling pathway.
BACKGROUND: Status Epilepticus (SE) is a common neurological emergency associated with a high rate of functional decline and mortality. Large randomized trials have addressed the early phases of treatment for convulsive SE. However, evidence regarding third-line anesthetic treatment and the treatment of nonconvulsive status epilepticus (NCSE) is scarce. One trial addressing management of refractory SE with deep general anesthesia was terminated early due to insufficient recruitment. Multicenter prospective registries, including the Sustained Effort Network for treatment of Status Epilepticus (SENSE), have shed some light on these questions, but many answers are still lacking, such as the influence exerted by distinct EEG patterns in NCSE on the outcome. We therefore initiated a new prospective multicenter observational registry to collect clinical and EEG data that combined may further help in clinical decision-making and defining SE.
METHODS: Sustained effort network for treatment of status epilepticus/European Academy of Neurology Registry on refractory Status Epilepticus (SENSE-II/AROUSE) is a prospective, multicenter registry for patients treated for SE. The primary objectives are to document patient and SE characteristics, treatment modalities, EEG, neuroimaging data, and outcome of consecutive adults admitted for SE treatment in each of the participating centers and to identify factors associated with outcome and refractoriness. To reach sufficient statistical power for multivariate analysis, a cohort size of 3000 patients is targeted.
DISCUSSION: The data collected for the registry will provide both valuable EEG data and information about specific treatment steps in different patient groups with SE. Eventually, the data will support clinical decision-making and may further guide the planning of clinical trials. Finally, it could help to redefine NCSE and its management.
TRIAL REGISTRATION: NCT number: NCT05839418.
FIELD: medicine. ^ SUBSTANCE: claimed invention relates to medicine. Cleaning composition removes contaminations and soiling substances from skin surface and contains thermoplastic polymer and water-soluble neutral oligosaccharide. In one version of execution cleaning composition contains polymethylmetacrilate and water-soluble starch. ^ EFFECT: invention describes paper product, which contains cleaning composition. ^ 20 cl, 4 tbl, 2 ex
The immediate treatment arm participants will be shipped an active Fisher Wallace device limited to Level 2 output even if a participant raises the dial beyond that. The participant will remain with the active device for the full 8 weeks.
1. Rinse the Sep-Pak cartridge with 10 mL methanol as follows: fill a 10-mL syringe with 10 mL methanol, attach the syringe to the longer end of the Sep-Pak cartridge, and push the methanol through the cartridge. Discard the eluate in a safe and approved manner.
  2. Similarly, rinse the cartridge with 10 mL water. Ensure that the cartridge is kept wet and that there is no air bubble present. If an air bubble is present, rinse the cartridge with additional 5 mL of water. Discard the eluate.
A blonding agent for changing the natural colour of keratinic fibres, in particular human hair, which contains a) sodium percarbonate, b) sodium chloride and further from 0 to about 8 % by weight of water. Preferably, the sodium carbonate - hydrogen peroxide comprises from 1 to 50 wt.% of the composition. Preferably, the sodium chloride comprises 0.1 to 5 wt.% of the blonding agent. Preferably, the cosmetic agent further comprises at least one inorganic salt of a peroxosulfuric acid (e.g. potassium peroxodisulfate, ammonium peroxodisulphate, sodium peroxodisulfate). The composition may further comprise an inorganic alkalising agent that is solid at 20 °C and 1013 mbar (e.g. sodium silicate or sodium metasilicate). The composition may further comprise a complexing agent (e.g. EDTA). Also claimed is a method for lightening keratinic fibers, wherein a blonding agent as described is mixed with water, applied immediately to the keratin-containing fibres, left on the fibres for 5 to 60 minutes, and subsequently rinsed off.
FIELD: medicine. SUBSTANCE: described are new diaryl-5,6-condensed heterocyclic acids of general formula I:   wherein   are as defined in claim 1 which are antagonists of effects of lenkotrienes. Compounds are useful as antiasthmatic, antiallergic, antiinflammatory and cytoprotective agents. They are also useful in treating spasms of cerebrum, nephrite, kidney glomeruluses, hepatitis, endotoxicosis, uvent and tearing away of allotransplantate. Also described is pharmaceutical composition and method of protection from effects of leukotrienes. EFFECT: improved properties of the title compounds. 12 cl, 123 ex
Clostridium difficile is currently the most frequently identified pathogen causing antibiotic-associated diarrhoea and the main cause of nosocomial diarrhoea. In regard to observed worldwide increase rate of infection and mortality from CDI the prevention of Clostridium difficile infections seems to be crucial, especially in patients at CDI high risk. So far, it has not been unambiguously proven that probiotics are effective in the prevention of Clostridium difficile infection among patients undergoing antibiotic therapy.

The Lactobacillus plantarum 299v (LP299v) is a Gram-positive lactic acid bacteria that naturally occurs on the surface of human intestinal mucosa. Specific properties to the gut mucosa colonization are due to mannose-dependent adhesion of LP299v to the epithelium of human intestines.This ability of LP299v leads to reduction of bacterial translocation from the intestinal lumen into the blood vessels, can prevent adhesion of many pathogens to intestinal epithelium and modulate the inflammatory response of the epithelium. The strain 299v of Lactobacillus plantarum has been found to decrease the severity of gastrointestinal adverse effects during antibiotic therapy. Limited data are available regarding the efficacy of LP299v for preventing Clostridium difficile infections.
Patients who are randomized to receive Dilapan, will have 3-5 rods of Dilapan-S® inserted in their cervix by the supervising provider, under aseptic precautions with a speculum exam, either digitally or using a sponge forceps, as per manufacturer's recommendations. The Bishop score at the time of eligibility assessment and number of rods inserted will be recorded. Dilapan will be left in cervix for 12 hours. Patients will be allowed to ambulate, shower and have light meals as long as they meet the criteria based on institutional guidelines for intermittent fetal heart monitoring. "Nothing per vagina" including douching and no bathing is allowed.